Research output per year
Research output per year
Personal profile
Expertises
Responsible for the production of cellular products for patients treated with immunotherapy.
Main research areas
Research focus is in the area of molecular and cellular tumor immunology which includes both basic research and development of novel molecular immunotherapeutic strategies for treatment of cancer.
Current research
Develop isolation and expansion methods for tumor-infiltrating lymphocyte (TIL) and to produce large-scale GMP-grade TIL products for adoptive cell therapy (ACT) clinical trials for melanoma and other solid tumors.
Development and exploitation of novel costimulatory chimeric antigen receptors (CARs) to be used ACT studies.
Fingerprint
Dive into the research topics where Ozcan Met is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
Mortensen, R. E. J., Holmström, M. O., Lisle, T. L., Hasselby, J. P., Willemoe, G. L., Met, Ö., Marie Svane, I., Johansen, J., Nielsen, D. L., Chen, I. M. & Andersen, M. H., 22 Mar 2023, In: Journal for ImmunoTherapy of Cancer. 11, 3, e006432.Research output: Contribution to journal › Journal article › Research › peer-review
1 Citation (Scopus) -
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
Klausen, U., Grauslund, J. H., Jørgensen, N. G. D., Ahmad, S. M., Jonassen, M., Weis-Banke, S. E., Martinenaite, E., Pedersen, L. B., Lisle, T. L., Gang, A. O., Enggaard, L., Hansen, M., Holmström, M. O., Met, Ö., Svane, I. M., Niemann, C. U., Pedersen, L. M. & Andersen, M. H., 2022, In: Frontiers in Oncology. 12, p. 1-13 13 p., 1023015.Research output: Contribution to journal › Journal article › Research › peer-review
-
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
Weis-Banke, S. E., Lisle, T. L., Perez-Penco, M., Schina, A., Hübbe, M. L., Siersbæk, M., Holmström, M. O., Jørgensen, M. A., Marie Svane, I., Met, Ö., Ødum, N., Madsen, D. H., Donia, M., Grøntved, L. & Andersen, M. H., 1 Oct 2022, In: Journal for ImmunoTherapy of Cancer. 10, 10, e005326.Research output: Contribution to journal › Journal article › Research › peer-review
1 Citation (Scopus) -
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S., George, M. M., Venkatesh, D., Ghosh, A., Hoyos, D., Molvi, Z., Kamaz, B., Marneth, A. E., Duke, W., Leventhal, M. J., Jan, M., & 23 others, 15 Jun 2022, In: Science translational medicine. 14, 649, p. eaba4380 eaba4380.Research output: Contribution to journal › Journal article › Research › peer-review
4 Citations (Scopus) -
Clinical advances and ongoing trials on mRNA vaccines for cancer treatment
Lorentzen, C. L., Haanen, J. B., Met, Ö. & Svane, I. M., Oct 2022, In: The Lancet Oncology. 23, 10, p. e450-e458Research output: Contribution to journal › Review › peer-review